The role of nonsedating antihistamines in asthma therapy

Allergy and Asthma Proceedings

Volumn 24, Issue 4, 2003, Pages 239-252

  Zitt, Myron J ^a,b  

^a STONY BROOK UNIVERSITY   (United States)

^b Queens Long Island Medical Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID; ASTEMIZOLE; AZATADINE; AZELASTINE; CALCIMYCIN; CETIRIZINE; DIPHENHYDRAMINE; HISTAMINE RECEPTOR; HYDROXYZINE; KETOTIFEN; LORATADINE; TERFENADINE;

ALLERGIC RHINITIS; ASTHMA; BASOPHIL; CONCENTRATION RESPONSE; CONFERENCE PAPER; DOSE RESPONSE; DRUG MEGADOSE; ENDOTHELIUM CELL; EPITHELIUM CELL; HUMAN; IN VITRO STUDY; LUNG FUNCTION; MACROPHAGE; MAST CELL; MOTOR PERFORMANCE; REDUCTION; T LYMPHOCYTE; WELLBEING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASTHMA; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; EOSINOPHILS; EPITHELIAL CELLS; HISTAMINE; HISTAMINE AGONISTS; HUMANS; HYPNOTICS AND SEDATIVES; MACROPHAGES, ALVEOLAR; MAST CELLS; PSYCHOMOTOR PERFORMANCE; T-LYMPHOCYTES;

EID: 0141628538     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (100)

1. Herxheimer HG. Antihistamines in bronchial asthma. Lancet 2:469, 1981.
2. Levy LI, and Seabury JH. Spirometric evaluation of Benadryl in asthma. J Allergy 18:244-250, 1947.
3. Schuller DE. The spectrum of antihistamines adversely affecting pulmonary function in asthmatic children. J Allergy Clin Immunol 71:147, 1983 (Abs).
4. Sly RM, and Kemp JP. The American Academy of Allergy and Immunology Committee on Drugs. The use of antihistamines in patients with asthma. J Allergy Clin Immunol 82:481-482, 1988.
5. Lantner R, and Tobin MC. Pharmacist advice to asthmatics regarding antihistamine use. Ann Allergy 66:411-413, 1991.
6. Spector SL, and Niklas RA (Eds). Practice parameters for the diagnosis and treatment of asthma. J Allergy Clin Immunol 96:789-791, 1995.
7. White MV, and Kaliner MA. Mediators of allergic rhinitis. J Allergy Clin Immunol 90:699-704, 1992.
8. Bousquet J, Van Cauwenberge P, and Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108:S147-S334, 2001.
9. Cummiskey J. Exercise-induced asthma: an overview. Am J Med Sci 322:200-203, 2001.
10. Vally H, de Klerk N, and Thompson PJ. Alcoholic drinks: important triggers for asthma. J Allergy Clin Immunol 105:462-467, 2000.
11. Middleton E, Reed C, Ellis E, et al. Antihistamines. In Allergy: Principles and Practice, 5th ed. Estelle E and Simons R (Eds.). St Louis, MO: CV Mosby, 612-637, 1998.
12. 1 Antihistamines in Allergic Disease. New York: Marcel Dekker, 108-139, 2002.
13. Galli SJ, Maurer M, and Lantz CS. Mast cells as sentinels of innate immunity. Curr Opin Immunol 11:53-59, 1999.
14. Lindstedt KA, Kokkonen JO, and Kovanen PT. Soluble heparin proteoglycans released from stimulated mast cells induce uptake of low-density lipoproteins by macrophages via scavenger receptor-mediated phagocytosis. J Lipid Res 33:65-75, 1992.
15. Gordon JR, Burd PR, and Galli SJ. Mast cells as a source of multifunctional cytokines. Immunol Today 11:458-464, 1990.
16. Bradding P, Roberts JA, Britten KM, et al. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 10:471-480, 1994.
17. Bradding P, Feather IH, Wilson S, et al. Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid. Am J Respir Crit Care Med 151:1900-1906, 1995.
18. Bradding P, Feather IH, Howarth PH, et al. Interleukin 4 is localized to and released by human mast cells. J Exp Med 176:1381-1386, 1992.
19. Busse WW, and Lemanske RF Jr. Asthma. N Engl J Med 344:350-362, 2001.
20. 1-receptor antagonists). J Allergy Clin Immunol 90:705-715, 1992.
21. 1-antihistamines in the skin. J Allergy Clin Immunol 110:777-783, 2002.
22. Monroe EW, Daly AF, and Shalhoub RF. Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines. J Allergy Clin Immunol 99:S798-S806, 1997.
23. Naclerio RM. Inhibition of mediator release during the early reaction to antigen. J Allergy Clin Immunol 90:715-719, 1992.
24. Naclerio RM, Proud D, Kagey-Sobotka A, et al. The effect of cetirizine on early allergic response. Laryngoscope 99:596-599, 1989.
25. Shin MH, Baroody F, Proud D, et al. The effect of azelastine on the early allergic response. Clin Exp Allergy 22:289-295, 1992.
26. Charlesworth EN, Kagey-Sobotka A, Norman PS, et al. Effect of cetirizine on mast cell-mediator release and cellular traffic during the cutaneous late-phase reaction. J Allergy Clin Immunol 83:905-912, 1989.
27. Jacobi HH, Skov PS, Poulsen LK, et al. Histamine and tryptase in nasal lavage fluid after allergen challenge: effect of 1 week of pretreatment with intranasal azelastine or systemic cetirizine. J Allergy Clin Immunol 103:768-772, 1999.
28. 1-receptor antagonists assessed by nasal challenge. J Allergy Clin Immunol 82:881-887, 1988.
29. Togias AG, Naclerio RM, Warner J, et al. Demonstration of inhibition of mediator release from human mast cells by azatadine base. In vivo and in vitro evaluation. JAMA 255:225-229, 1986.
30. 2 antihistamines on "allergic" histamine release and its inhibition by histamine. J Pharmacol Exp Ther 192:441-450, 1975.
31. De Paulis A, Donte V, Onorate AM, et al. Fexofenadine inhibits the release of mediators and IL-4 from human FcεRI+ cells. Allergy 54:278, 1999 (Abs).
32. Genovese A, Patella V, De Crescenzo G, et al. Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human FcεRI+ cells. Clin Exp Allergy 27:559-567, 1997.
33. Berthon B, Taudou G, Combettes L, et al. In vitro inhibition, by loratadine and descarboxyethoxyloratadine, of histamine release from human basophils, and of histamine release and intracellular calcium fluxes in rat basophilic leukemia cells (RBL-2H3). Biochem Pharmacol 47:789-794, 1994.
34. 1 antagonist, desethoxylcarbonyl-loratadine. J Allergy Clin Immunol 93:494-500, 1994.
35. 1-antagonist descarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines. Exp Dermatol 4:272-276, 1995.
36. Little MM, and Casale TB. Azelastine inhibits IgE-mediated human basophil histamine release. J Allergy Clin Immunol 83:862-865, 1989.
37. Shichijo M, Inagaki N, Nakai N, et al. The effects of anti-asthma drugs on mediator release from cultured human mast cells. Clin Exp Allergy 28:1228-1236, 1998.
38. Little MM, Wood DR, and Casale TB. Azelastine inhibits stimulated histamine release from human lung tissue in vitro but does not alter cyclic nucleotide content. Agents Actions 28:16-21, 1989.
39. Miki I, Kusano A, Ohta S, et al. Histamine enhanced the TNF-alpha-induced expression of E-selectin and ICAM-1 on vascular endothelial cells. Cell Immunol 71:285-288, 1996.
40. Jeannin P, Delneste Y, Gosset P, et al. Histamine induces interleukin-8 secretion by endothelial cells. Blood 84:2229-2233, 1994.
41. Molet S, Gosset P, Lassalle P, et al. Inhibitory activity of loratadine and descarboethoxyloratadine on histamine-induced activation of endothelial cells. Clin Exp Allergy 27:1167-1174, 1997.
42. Kyan-Aung U, Hallsworth M, Haskard D, et al. The effects of cetirizine on the adhesion of human eosinophils and neutrophils to cultured human umbilical vein endothelial cells. J Allergy Clin Immunol 90:270-272, 1992.
43. Abdelaziz MM, Devalia JL, Khair OA, et al. Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol 101:410-420, 1998.
44. Paolieri F, Battifora M, Riccio AM, et al. Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines. Ann Allergy Asthma Immunol 81:601-607, 1998.
45. Marshall GD Jr. Therapeutic options in allergic disease: Antihistamines as systemic antiallergenic agents. J Allergy Clin Immunol 106:S303-S309, 2000.
46. Ciprandi G, Tosca M, Ricca V, et al. Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its antiallergic activity. Clin Exp Allergy 27:1160-1166, 1997.
47. Ciprandi G, Pronzato C, Passalacqua G, et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity. J Allergy Clin Immunol 98:1088-1096, 1996.
48. Ciprandi G, Buscaglia S, Pesce G, et al. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. J Allergy Clin Immunol 95:612-621, 1995.
49. Ciprandi G, Buscaglia S, Catrullo A, et al. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. Clin Exp Allergy 27:182-191, 1997.
50. Ciprandi G, Pronzato C, Ricca V, et al. Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM-1 expression. Clin Exp Allergy 27:1175-1183, 1997.
51. 1-blockers in seasonal allergic rhinitis. Allergy 52:1022-1025, 1997.
52. Lebel B, Bousquet J, Czarlewski W, et al. Loratadine reduces RANTES release by an epithelial cell line. J Allergy Clin Immunol 99:S444, 1997 (Abs).
53. Vignola AM, Crampette L, Mondain M, et al. Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells. Allergy 50:200-203, 1995.
54. Papi A, Papadopoulos NG, Stanciu LA, et al. Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promotor activation in respiratory epithelial cells. J Allergy Clin Immunol 108:221-228, 2001.
55. Gern JE. Rhinovirus respiratory infections and asthma. Dis Mon 49:185-200, 2003.
56. Bianco A, Mazzarella G, Bresciani M, et al. Virus-induced asthma. Monaldi Arch Chest Dis 57:188-190, 2002.
57. Marone G, Gentile M, Petraroli A, et al. Histamine-induced activation of human lung macrophages. Int Arch Allergy Immunol 124:249-252, 2001.
58. Gonzalo JA, Lloyd CM, Kremer L, et al. Eosinophil recruitment to the lung in a murine model of allergic inflammation. The role of T cells, chemokines, and adhesion receptors. J Clin Invest 98:2332-2345, 1996.
59. Ritz SA, Gajewska BU, Stampfli MR, et al. Determinants of the immune-inflammatory response in allergic airway inflammation: overview of antigen presentation and cellular activation. J Allergy Clin Immunol 106:S206-S212, 2000.
60. Munakata Y, Umezawa Y, Iwata S, et al. Specific inhibition of TH2-type cytokine production from human peripheral T cells by terfenadine in vitro. Clin Exp Allergy 29:1281-1286, 1999.
61. Gelfand EW, Cui ZH, Takeda K, et al. Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness. J Allergy Clin Immunol 110:85-95, 2002.
62. 1 receptor blockade on the early and late response to cutaneous allergen challenge. J Pharmacol Exp Ther 262:964-970, 1992.
63. Thomson L, Blaylock MG, Sexton DW, et al. Cetirizine and levocetirizine inhibit eotaxin-induced eosinophil transendothelial migration through human dermal or lung microvascular endothelial cells. Clin Exp Allergy 32:1187-1192, 2002.
64. Agrawal DK, Berro A, and Townley RG. Desloratadine attenuation of eosinophil chemotaxis, adhesion, and superoxide generation. Allergy 55:276, 2000 (Abs).
65. Kapsali T, Horowitz E, Diemer F, et al. Rhinitis is ubiquitous in allergic asthmatics. J Allergy Clin Immunol 99:138, 1997 (Abs).
66. Smith JM. Epidemiology and natural history of asthma, allergic rhinitis, and atopic dermatitis (eczema). In Allergy Principles and Practice, 3rd ed. Middleton E Jr, Reed CE, Ellis EF, Adkinson NJ Jr, and Ranginger JW (Eds). St. Louis, MO: Mosby, 891-929, 1988.
67. Ramsdale EH, Morris MM, Roberts RS, et al. Asymptomatic bronchial hyperresponsiveness in rhinitis. J Allergy Clin Immunol 75:573-577, 1985.
68. Simons FE. Allergic rhinobronchitis: the asthma-allergic rhinitis link. J Allergy Clin Immunol 104:534-540, 1999.
69. Hellings PW, Hessel EM, Van Den Oord JJ, et al. Eosinophilic rhinitis accompanies the development of lower airway inflammation and hyper-reactivity in sensitized mice exposed to aerosolized allergen. Clin Exp Allergy 31:782-790, 2001.
70. Braunstahl GJ, Overbeek SE, Kleinjan A, et al. Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. J Allergy Clin Immunol 107:469-476, 2001.
71. Braunstahl GJ, Kleinjan A, Overbeek SE, et al. Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med 161:2051-2057, 2000.
72. Corren J, Harris AG, Aaronson D, et al. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J Allergy Clin Immunol 100:781-788, 1997.
73. Corren J, Adinoff AD, and Irvin CG. Changes in bronchial responsiveness following nasal provocation with allergen. J Allergy Clin Immunol 89:611-618, 1992.
74. Crystal-Peters J, Neslusan C, Crown WH, et al. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol 109:57-62, 2002.
75. Grant JA, Nicodemus CF, Findlay SR, et al. Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 95:923-932, 1995.
76. de Bruin-Weller MS, Rijssenbeek-Nouwens LH, and de Monchy JG. Lack of effect of cetirizine on early and late asthmatic response after allergen challenge. J Allergy Clin Immunol 94:231-239, 1994.
77. Kelemen J, Cserhati E, Gegesi Kiss A, et al. The protective effect of cetirizine on exercise induced asthma. Eur J Allergy Clin Immunol 48:32, 1993 (Abs).
78. 1 antagonist, on allergen- and exercise-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 85:632-641, 1990.
79. Ghosh SK, De Vos C, and Patel KR. Effect of cetirizine on exercise-induced bronchoconstriction in patients with asthma. Am Rev Respir Dis 141:A836, 1990 (Abs).
80. 4-induced bronchoconstriction in patients with atopic asthma. J Allergy Clin Immunol 87:1010-1013, 1991.
81. Bergmann RL, Edenharter G, Bergmann KE, et al. Atopic dermatitis in early infancy predicts allergic airway disease at 5 years. Clin Exp Allergy 28:965-970, 1998.
82. Warner JO. A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow-up. J Allergy Clin Immunol 108:929-937, 2001.
83. Schenkel E, and the Desloratadine Study Group. Desloratadine improved SAR symptoms in patients with mild-to-moderate asthma and SAR. Ann Allergy Asthma Immunol 86:110, 2001 (Abs).
84. Ratner PH, and the Desloratadine Study Group. Desloratadine improved asthma symptoms and reduced bronchodilator use in 2 studies of patients with asthma and SAR. Ann Allergy Asthma Immunol 86:109, 2001 (Abs).
85. Baena-Cagnani CE. Desloratadine activity in concurrent seasonal allergic rhinitis and asthma. Allergy 56:21-27, 2001.
86. Busse WW, Middleton E, Storms W, et al. Corticosteroid-sparing effect of azelastine in the management of bronchial asthma. Am J Respir Crit Care Med 153:122-127, 1996.
87. Azelastine-Asthma Study Group. An evaluation of the efficacy and safety of azelastine in patients with chronic asthma. J Allergy Clin Immunol 97:1218-1224, 1996.
88. Wessel F, Marazzi P, Soto-Roman L, et al. The effect of the nonsedating antihistamines loratadine and terfenadine on seasonal allergic rhinitis in patients with controlled bronchial asthma. Adv Ther 14:199-208, 1997.
89. 1-receptor antagonist, terfenadine, in chronic severe asthma. Br J Clin Pharmacol 39:671-675, 1995.
90. Taytard A, Beaumont D, Pujet JC, et al. Treatment of bronchial asthma with terfenadine: a randomised controlled trial. Br J Clin Pharmacol 24:743-746, 1987.
91. Kaliner M, Gottleib G, Lieberman A, et al. Safety of fexofenadine HCl in asthmatic patients requiring inhaled corticosteroids in accordance with NHLBI guidelines. J Allergy Clin Immunol 105:S368, 2000 (Abs).
92. Aaronson DW. Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma. Ann Allergy Asthma Immunol 76:440-446, 1996.
93. Spector SL, Nicodemus CF, Corren J, et al. Comparison of the bronchodilatory effects of cetirizine, albuterol, and both together versus placebo in patients with mild-to-moderate asthma. J Allergy Clin Immunol 96:174-181, 1995.
94. 1-receptor antagonist in the treatment of grass pollen sensitive asthma. Br J Clin Pharmacol 30:229-235, 1990.
95. 1-receptor antagonists: safety issues. Ann Allergy Asthma Immunol 83:481-488, 1999.
96. Pratt C, Brown AM, Rampe D, et al. Cardiovascular safety of fexofenadine HCl. Clin Exp Allergy 29:212-216, 1999.
97. Hindmarch I, and Shamsi Z. Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects. Clin Exp Allergy 29:133-142, 1999.
98. Clarinex® (desloratadine) Tablets, Reditabs Tablets. Package Insert. Schering Corporation, Kenilworth, NJ, 2002.
99. Howarth PH, Stern MA, Roi L, et al. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 104:927-933, 1999.
100. Russell T, Stoltz M, and Weir S. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin Pharmacol Ther 64:612-621, 1998.